MyStart Health review: November 2026 prices, terms and what to verify
As of November 20, 2026, MyStart Health has no current price in this dataset: it was not part of the November 20, 2026 re-read, and no figure is shown rather than an old one presented as current. Check its own checkout before you enroll.
Released · Last reviewed · how we verify
Why no current price is shown
Not in the November 20 re-read; no price published here. This site publishes no figure rather than an estimate or an outdated price presented as current. The August 2026 capture is kept in the open dataset as history, dated.
FDA warning letters
FDA’s warning-letter index lists warning letter 714755 (dated September 9, 2025, subject “Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet (Telehealth)”) to MyStart Health; no close-out letter is listed. A warning letter is FDA’s formal notice of alleged violations, not a recall, ban or court finding.
Limitations: five things to get in writing before you pay
Ask for the all-in price at your current dose and at the maintenance dose; the amount charged today and whether it recurs monthly or is prepaid; the licensed pharmacy that fills the prescription; the cancellation and refund terms, word for word; and what happens to your price when the dose goes up. Compounded tirzepatide and semaglutide are not FDA-approved and are not the same products as Zepbound or Wegovy.
Frequently asked
Does MyStart Health charge a membership fee?
MyStart Health’s page did not show a membership fee that could be confirmed on November 20, 2026, so check the checkout summary for any recurring fee.
Does MyStart Health take insurance?
Not for compounded medication. MyStart Health is a cash-pay program in this dataset (August 2026 capture), and insurers do not cover compounded GLP-1s. If your plan covers Zepbound or Wegovy, check that first, because a covered brand prescription usually costs less than any cash price.
Which states does MyStart Health serve?
MyStart Health’s published coverage in the August 2026 capture was: not published. Telehealth prescribing depends on state licensing and changes often, so confirm your state at the start of the intake. The state pages list what each program publishes.
Sources
- FDA: Concerns with unapproved GLP-1 drugs used for weight loss (content current as of October 1, 2026; read November 20, 2026)
- Federal Register 91 FR 23431: proposed 503B bulks-list decision for semaglutide, tirzepatide and liraglutide (May 1, 2026; no final notice found as of November 20, 2026)
- Zepbound (tirzepatide) prescribing information on DailyMed (read November 20, 2026)
- Wegovy (semaglutide) prescribing information on DailyMed (read November 20, 2026)
- FDA warning letter 714755 to MyStart Health (dated 2025-09-09, posted 2025-09-16; read November 20, 2026)